TIM-3 and CEACAM1 do not interact in cis and in trans

Eur J Immunol. 2020 Aug;50(8):1126-1141. doi: 10.1002/eji.201948400. Epub 2020 Apr 28.

Abstract

TIM-3 has been considered as a target in cancer immunotherapy. In T cells, inhibitory as well as activating functions have been ascribed to this molecule. Its role may therefore depend on the state of T cells and on the presence of interaction partners capable to perform functional pairing. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM1) has been proposed to bind TIM-3 and to regulate its function. Using a T cell reporter platform we confirmed CEACAM1-mediated inhibition, but CEACAM1 did not functionally engage TIM-3. TIM-3 and CEACAM1 coexpression was limited to a small subset of activated T cells. Moreover, results obtained in extensive binding studies were not in support of an interaction between TIM-3 and CEACAM1. Cytoplasmic sequences derived from TIM-3 induced inhibitory signaling in our human T cell reporter system. Our results indicate that TIM-3 functions are independent of CEACAM1 and that this receptor has the capability to promote inhibitory signaling pathways in human T cells.

Keywords: CEACAM1; Coinhibition; Costimulation; T-cell activation; TIM-3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / physiology*
  • Cell Adhesion Molecules / physiology*
  • Fluorescence Resonance Energy Transfer
  • HEK293 Cells
  • Hepatitis A Virus Cellular Receptor 2 / analysis
  • Hepatitis A Virus Cellular Receptor 2 / physiology*
  • Humans
  • Jurkat Cells
  • Lymphocyte Activation
  • Signal Transduction / physiology
  • T-Lymphocytes / immunology

Substances

  • Antigens, CD
  • CD66 antigens
  • Cell Adhesion Molecules
  • HAVCR2 protein, human
  • Hepatitis A Virus Cellular Receptor 2